NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis.
NICE TA916: Bimekizumab for treating active psoriatic arthritis. ICB commissioned (decision date November 2023)
NICE TA918: Bimekizumab for treating axial spondyloarthritis. ICB commissioned (decision date November 2023)
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
